MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic characterization of small-molecule inhibitors that recapitulate the synthetic lethal phenotype has not been described. MRTX1719 select...

Descripción completa

Detalles Bibliográficos
Autores principales: Engstrom, Lars D., Aranda, Ruth, Waters, Laura, Moya, Krystal, Bowcut, Vickie, Vegar, Laura, Trinh, David, Hebbert, Allan, Smith, Christopher R., Kulyk, Svitlana, Lawson, J. David, He, Leo, Hover, Laura D., Fernandez-Banet, Julio, Hallin, Jill, Vanderpool, Darin, Briere, David M., Blaj, Alice, Marx, Matthew A., Rodon, Jordi, Offin, Michael, Arbour, Kathryn C., Johnson, Melissa L., Kwiatkowski, David J., Jänne, Pasi A., Haddox, Candace L., Papadopoulos, Kyriakos P., Henry, Jason T., Leventakos, Konstantinos, Christensen, James G., Shazer, Ronald, Olson, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618744/
https://www.ncbi.nlm.nih.gov/pubmed/37552839
http://dx.doi.org/10.1158/2159-8290.CD-23-0669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618744/
https://www.ncbi.nlm.nih.gov/pubmed/37552839
http://dx.doi.org/10.1158/2159-8290.CD-23-0669

Ejemplares similares